Scarica l'app Stockscreener
198.71
1.11%
-2.24
Dopo l'orario di chiusura:
198.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$200.95
Aprire:
$198.93
Volume 24 ore:
7.60M
Relative Volume:
1.08
Capitalizzazione di mercato:
$351.47B
Reddito:
$61.16B
Utile/perdita netta:
$4.19B
Rapporto P/E:
84.15
EPS:
2.3614
Flusso di cassa netto:
$17.82B
1 W Prestazione:
-4.64%
1M Prestazione:
-3.16%
6M Prestazione:
-12.84%
1 anno Prestazione:
+10.17%
Intervallo 1D:
$197.14
$200.25
Intervallo di 1 settimana:
$197.14
$208.33
Portata 52W:
$176.57
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
198.71 | 351.47B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
883.96 | 789.69B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.50 | 547.64B | 96.36B | 21.04B | 17.80B | 8.6488 |
AZN
Astrazeneca Plc
|
189.75 | 294.27B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
145.47 | 277.58B | 54.72B | 14.02B | 15.32B | 7.1855 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Inc. $ABBV Shares Acquired by Vanguard Group Inc. - MarketBeat
Sanctuary Advisors LLC Buys 6,911 Shares of AbbVie Inc. $ABBV - MarketBeat
Richard C. Young & CO. LTD. Acquires 6,966 Shares of AbbVie Inc. $ABBV - MarketBeat
Polaris Capital Management LLC Sells 22,167 Shares of AbbVie Inc. $ABBV - MarketBeat
Axecap Investments LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AEGON ASSET MANAGEMENT UK Plc Sells 20,049 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug - Yahoo Finance
Golden Reserve Retirement LLC Invests $1.68 Million in AbbVie Inc. $ABBV - MarketBeat
Calamos Advisors LLC Grows Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Trading Down 1.1%Time to Sell? - MarketBeat
Therapeutics Stocks Q4 Earnings: AbbVie and Novavax Performance Analysis as of April 2026News and Statistics - IndexBox
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie Stock: Skyrizi and Rinvoq Already Cleared 2027 Guidance, But Does the Discount Still Make Sense? - TIKR.com
AbbVie’s move to revitalize Botox demand stymied by FDA questions - Crain's Chicago Business
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues - Yahoo! Finance Canada
US FDA rejects AbbVie's wrinkle treatment due to manufacturing concerns - Reuters
Biopharma company AbbVie to create 730 jobs in Durham - WRAL
Insights Into AbbVie (ABBV) Q1: Wall Street Projections for Key Metrics - Yahoo Finance
Turtle Creek Wealth Advisors LLC Has $4.74 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug - Benzinga
AbbVie (ABBV) Faces FDA Setback on TrenibotE Approval - GuruFocus
Quent Long Short Global Small Cap Fund LP Invests $2.17 Million in AbbVie Inc. $ABBV - MarketBeat
AbbVie anti-wrinkle therapy rejected at FDA (ABBV:NYSE) - Seeking Alpha
AbbVie Inc. $ABBV Shares Sold by Torray Investment Partners LLC - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Arizona State Retirement System - MarketBeat
AbbVie receives CRL from FDA regarding BLA for trenibotulinumtoxinE - TipRanks
Earnings Preview: AbbVie to Report Financial Results Pre-market on April 29 - Moomoo
AbbVie wrinkle treatment rejected by FDA over manufacturing issues - Investing.com Canada
AbbVie Gets FDA Complete Response Letter on TrenibotE BLA - marketscreener.com
FDA Requests Additional Information on AbbVie's Application for Neurotoxin - Moomoo
AbbVie Provides Update on TrenibotulinumtoxinE Biologics License Application in the U.S. - Investing News Network
AbbVie (ABBV) Receives Complete Response Letter from FDA on Tren - GuruFocus
US FDA declines to approve AbbVie's wrinkle treatment - marketscreener.com
AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S. - marketscreener.com
Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4 - Yahoo Finance
AbbVie’s aesthetic neurotoxin faces FDA manufacturing questions - Stock Titan
ABBV Maintains Overweight RatingPrice Target Lowered to $294 - GuruFocus
AbbVie Price Target Cut to $294.00/Share From $299.00 by Piper Sandler - Moomoo
Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus - Manufacturing Dive
AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results? - The Globe and Mail
Piper Sandler lowers Abbvie stock price target on IL-23 competition - Investing.com Canada
OLD National Bancorp IN Reduces Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Stake Boosted by Milestone Asset Management LLC - MarketBeat
AbbVie Announces $1.4B Investment in North Carolina - Contract Pharma
AbbVie to invest $1.4bn in North Carolina manufacturing campus - The Manufacturer
AbbVie price target lowered to $294 from $299 at Piper Sandler - TipRanks
HB Wealth Management LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie to Invest $1.4B in New Pharmaceutical Manufacturing Facility in Durham, North Carolina - REBusinessOnline
AbbVie opts for North Carolina to house $1.4bn manufacturing site - Pharmaceutical Technology
ABBV (AbbVie Inc.) posts narrow Q4 2025 EPS beat, shares dip slightly in daily trading.Earnings Volatility - Cổng thông tin điện tử Tỉnh Sơn La
AbbVie to invest $1.4 billion in NC facility - The Pharma Letter
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.33%
6.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):